-
1.
公开(公告)号:JP2012144548A
公开(公告)日:2012-08-02
申请号:JP2012054181
申请日:2012-03-12
Applicant: Chelsea Thrapeutics Inc , チェルシー サラピューティックス インク.
Inventor: JOENSSON STIG , ANDERSSON GUNNAR , WELLMAR ULF , FRITZON INGELA
IPC: C07C233/63 , A61K31/195 , A61K31/196 , A61P1/04 , A61P3/10 , A61P17/06 , A61P19/02 , A61P25/00 , A61P29/00 , A61P35/00 , A61P37/06 , C07C233/54 , C07C233/75 , C07C233/88 , C07C235/56 , C07C275/36 , C07C321/28 , C07C321/30 , C07C323/59 , C07C323/63 , C07D207/06 , C07D211/14 , C07D295/096 , C07D295/155
CPC classification number: C07C233/54 , C07C233/63 , C07C233/75 , C07C235/56 , C07C275/36 , C07C323/59 , C07C323/63 , C07C2601/02 , C07D207/06 , C07D211/14 , C07D295/096 , C07D295/155
Abstract: PROBLEM TO BE SOLVED: To solve the problem in which conventional compounds cannot sufficiently exert an inhibitory effect on DHODH (dihydroorotate dehydrogenase).SOLUTION: There are provided a compound such as 2-(cyclopropanecarbonyl-amino)-5-(2-phenylacetylamino-phenoxy)-benzoic acid, and a compound selected from salts thereof coupled with pharmaceutically allowable inorganic cations, which are used to provide the compound and pharmaceutical composition effective for clinical treatment of autoimmune disease, inflammatory disease, rejection to organ transplant and malignant neoplasm.
Abstract translation: 待解决的问题:为了解决常规化合物不能充分发挥对DHODH(二氢乳清酸脱氢酶)抑制作用的问题。 提供了一种化合物,例如2-(环丙烷羰基 - 氨基)-5-(2-苯基乙酰基氨基 - 苯氧基) - 苯甲酸,以及选自其药学上允许的无机阳离子的盐的化合物,其被使用 提供对于自身免疫性疾病,炎性疾病,器官移植排斥和恶性肿瘤的临床治疗有效的化合物和药物组合物。 版权所有(C)2012,JPO&INPIT